BioTuesdays

Tag - PRN

Profound Medical Logo

Nominees announced for 2020 Bloom Burton award

Arun Menawat, CEO of Profound Medical (NASDAQ:PROF; TSX:PRN), was one of three nominees for the 2020 Bloom Burton award, which honors an individual who has made the most significant contribution to Canada’s innovative...

Profound Medical Logo

Cowen starts Profound Medical at OP; PT $15 (U.S.)

Cowen launched coverage of Profound Medical (NASDAQ:PROF; TSX:PRN) with an “outperform” rating and $15 (U.S.) price target. The stock closed at $9.74 on March 31. “[Profound’s] TULSA-PRO is a proprietary platform that...

Profound Medical Logo

Mackie Research ups Profound Medical to speculative buy

Mackie Research upgraded Profound Medical (TSX:PRN; NASDAQ:PROF) to “speculative buy” from “hold,” but reduced its price target to $16.20 from $26.10 due to the anticipated impact of the coronavirus. The stock closed at...

Profound Medical Logo

Canaccord ups Profound Medical PT to $20 from $14

Canaccord Genuity raised its price target for Profound Medical (NASDAQ:PROF; TSX:PRN) to $20 from $14 after the company announced preliminary Q4-2019 results. Shares of Profound were quoted at $14.72, up $1.73, or 13%...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.